Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus

Arroyo, Monica S.; Krueger, Darcy A.; Broomall, Eileen; Stevenson, Charles B.; Franz, David Neal

doi:10.1016/j.pediatrneurol.2017.04.008

Cited by 19 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In certain situations using higher dosages may be worth the risk, as for example with large unresectable astrocytomas or medically refractory epilepsy (Figure 9; Arroyo, Krueger, Broomall, Stevenson, & Franz, 2017). As such, regardless of the particular feature of the disease that leads to their initiation, therapeutic effects can be expected for multiple aspects of the patient's condition.…”

Section: Treating the Patientmentioning

confidence: 99%

“…Although higher doses of mTOR with the cost of a higher incidence of side effects. In certain situations using higher dosages may be worth the risk, as for example with large unresectable astrocytomas or medically refractory epilepsy (Figure 9; Arroyo, Krueger, Broomall, Stevenson, & Franz, 2017). For most patients, however, we view mTOR inhibitors as disease modifying agents.…”

Section: Treating the Patientmentioning

confidence: 99%

See 1 more Smart Citation

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

Franz

Krueger

2018

American J of Med Genetics Pt C

View full text Add to dashboard Cite

Between 1993 and 2003, through experiments involving Drosophila sp., cancer biologists identified the protein kinase known as the mammalian target of rapamycin, its pathway, and its relationship to the genes responsible for tuberous sclerosis. Thereafter, clinical research has resulted in regulatory approval of mTOR inhibitors for four distinct manifestations of the disease: giant cell astrocytoma, angiomyolipoma, lymphangioleiomyomatosis, and epilepsy. These developments are summarized and the practical use of mTOR inhibitors to improve the lives of patients with tuberous sclerosis reviewed.

show abstract

Section: Treating the Patientmentioning

confidence: 99%

Section: Treating the Patientmentioning

confidence: 99%

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

Franz

Krueger

2018

American J of Med Genetics Pt C

View full text Add to dashboard Cite

show abstract

“…20 However, everolimus decreases protein levels, and has been shown to help maintain proper shunt functioning. [21][22][23] Thus, VP shunting in tandem with everolimus therapy may prolong shunt durability and is a worthwhile option in patients who are not candidates for ETV.…”

Section: Discussionmentioning

confidence: 99%

Orbital and nasal meningoencephaloceles secondary to chronic hydrocephalus: A rare cause of bilateral proptosis

et al. 2018

View full text Add to dashboard Cite

Introduction Orbital meningoencephalocele formation is primarily a result of congenital defects in the pediatric population and trauma of the anterior cranial fossa in adults. We present a unique case of nontraumatic nasal and orbital meningoencephaloceles presenting as bilateral proptosis with exotropia secondary to chronic hydrocephalus. Clinical presentation A 20-year-old male with a history of tuberous sclerosis, X-linked intellectual disability, and epilepsy presented to the emergency department with two days of nausea, emesis, seizures, and two months of progressive proptosis. Initial radiographs of the skull showed a "copper beaten" appearance, indicating chronically elevated intracranial pressure. Computed tomography imaging of the head demonstrated bilateral defects in the cribriform plate and anterior cranial fossa. Magnetic resonance imaging of the brain revealed triventricular hydrocephalus with meningoencephalocele extension into the nasal cavity and frontal horn herniation into the extraconal space of the orbits. The hydrocephalus was managed with ventriculoperitoneal shunt placement with rapid and complete resolution of the proptosis. Conclusion No reports have described bilateral proptosis as the presenting finding of orbital and nasal meningoencephaloceles in the absence of trauma or congenital defect. This case study demonstrates the management of meningoencephalocele formation secondary to chronic hydrocephalus.

show abstract

“…PI3K/AKT/mTOR inhibitors not only impact directly upon cancer cells but can also affect immune cell effector function and to modulate the tumor microenvironment. As single agent therapies, the efficacy of PI3K/AKT/mTOR inhibitors in the treatment of a variety of cancers has generally not been satisfactory and phase III clinical trials have not been reported yet in patients with ovarian cancer [92,93,94,95,96].…”

Section: Inhibitors Of the Mechanistic Target Of Rapamycin (Mtor) mentioning

confidence: 99%

“…A few rapalogs (Table 3) are currently used in clinical trials, out of which temsirolimus and everolimus have been granted FDA approval [92,93,94]. However, only modest therapeutic effects have been observed in all these malignancies since mTOR inhibitors may have more of a cytostatic rather than a cytotoxic effect, with a benefit mainly in terms of disease stabilization and progression free survival (PFS) improvement rather than tumor shrinkage.…”

Section: Monotherapy Trials Using Rapalogs (Mtor Inhibitors)mentioning

confidence: 99%

Kinase Inhibitors and Ovarian Cancer

Katopodis

Chudasama

Wander

et al. 2019

Cancers

View full text Add to dashboard Cite

Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.

show abstract

Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus

Cited by 19 publications

References 14 publications

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

Orbital and nasal meningoencephaloceles secondary to chronic hydrocephalus: A rare cause of bilateral proptosis

Kinase Inhibitors and Ovarian Cancer

Contact Info

Product

Resources

About